We know that a consistent positive sentiment reading will eventually translate to the stock price, but when? A recent example involving shares of Biotech companies may provide some insight:
No model can forecast with 100% certainty the magical ‘tipping point’ where sentiment insights translate to stock performance.
Shares of Biotech companies present a real-world case study. Following a tumultuous start to 2016, sentiment remained elevated. So far in 2017, we are seeing the long awaited breakout, with expectations of further gains ahead.
The BUZZ NextGen AI™ process applies proprietary artificial intelligence models across vast large scale datasets to identify patterns, trends and changing sentiment which can affect market based outcomes, providing the foundation for superior investment returns.
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was trading at $310.81 per share on Thursday afternoon, down $4.48 (-1.42%). Year-to-date, IBB has gained 17.12%, versus a 7.82% rise in the benchmark S&P 500 index during the same period.
This article is brought to you courtesy of Buzz Indexes.